Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
-
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the...
-
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
-
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...
-
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...
-
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric...
-
Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its...
-
On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3...